We sought to evaluate the potential of the thio-phosphoramidate oligonucleotide inhibitor of telomerase, imetelstat, as a drug candidate for treatment of esophageal cancer.
Our results showed that imetelstat inhibited telomerase activity in a dose-dependent manner in esophageal cancer cells.
